Engagement supports exploitation license pathway while advancing responsible, large-scale development of the Skaergaard ProjectCHARLOTTE, N.C., ...

Executives from Definium Therapeutics (NASDAQ:DFTX) outlined clinical, regulatory, and commercial priorities for its lead psychedelic-derived program during a management discussion, emphasizing multip ...

A home blood pressure telemonitoring (HBPT) program effectively reduced BP in real-world clinical settings, but its enrollment expenses increased overall costs. The HBPT program reduced BP clinic ...

VANCOUVER, BC / ACCESS Newswire / March 16, 2026 / Gamma Resources Ltd. (TSXV:GAMA)(OTCQB:GAMXF)(FRA:MRDN) ("Gamma" or the "Company") is pleased that it has engaged SWCA Environmental Consultants ("SW ...

Despite a pressing need to improve outcomes and address inequities in nursing homes, there is limited evidence about the specific factors required to successfully implement real-world interventions in ...

Medical University of South Carolina researchers report in Palliative and Supportive Care that early virtual palliative care for people living with dementia, as well as for their caregivers, is both ...

Cost overruns and schedule delays across the nuclear weapons agency's $30-billion construction portfolio have more than doubled since 2023.

Mave Health is listing the headset at $495 for pre-orders. It aims to ship devices to users in the U.S. and India in April 2026.

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC - an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit ...

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...

STELLAR-2, a randomized, double-blind, sham-controlled study, will evaluate the effects of salanersen when initiated ~6 months after onasemnogene abeparvovec-xioi in infants with SMA who received ...